Researchers have made a significant advancement in combating a uncommon genetic disorder that accelerates aging in children at an alarming rate. This breakthrough centers on “longevity genes” identified in individuals who achieve remarkable lifespans, frequently surpassing the century mark. A collaborative effort between scientists at the University of Bristol and IRCCS MultiMedica has revealed that these genes, which play a crucial role in preserving cardiovascular health as people age, possess the potential to mitigate some of the severe effects inflicted by this tragic condition.
The research, featured in the journal Signal Transduction and Targeted Therapy, marks the pioneering demonstration that a gene derived from exceptionally long-lived people can decelerate cardiac aging in an experimental model of Progeria. Medically termed Hutchinson-Gilford Progeria Syndrome (HGPS), this exceedingly rare and lethal ailment manifests as rapid aging symptoms in affected youngsters.
The root cause of Progeria lies in a specific mutation within the LMNA gene, resulting in the production of a detrimental protein known as progerin. This aberrant protein severely impairs standard cellular operations, with particularly devastating impacts on the heart and vascular system. Tragically, the majority of children suffering from this disorder succumb to cardiovascular failures during their adolescent years, although exceptional cases like Sammy Basso, recognized as the longest-surviving individual with Progeria, have defied the odds. Sammy Basso sadly passed away on October 24, 2024, having reached the age of 28.
Progerin exerts its destructive influence by compromising the stability of the cell nucleus, which serves as the central hub regulating all cellular processes. This nuclear instability hastens the aging process, most prominently within the cardiovascular framework.
Currently, the sole medication endorsed by the United States Food and Drug Administration (FDA) for this condition is lonafarnib, designed to diminish the buildup of progerin within cells. Ongoing clinical trials are evaluating the efficacy of combining lonafarnib with an investigational compound called Progerinin, aiming to assess if this dual therapy yields superior outcomes.
Investigating Longevity Genes from Supercentenarians
In pursuit of novel therapeutic avenues, Dr. Yan Qiu and Professor Paolo Madeddu from the Bristol Heart Institute joined forces with Professor Annibale Puca’s group at IRCCS MultiMedica in Italy. Their primary objective was to ascertain whether genetic elements from supercentenarians—those who live to extreme ages—could shield cells from the ravages induced by Progeria.
The investigators zeroed in on a specific gene called LAV-BPIFB4, which prior studies have established as a key supporter of robust cardiac and vascular performance throughout the aging process.
Employing mice genetically modified to replicate Progeria, the team documented initial cardiac abnormalities mirroring those observed in pediatric patients with the syndrome. Following administration of a solitary dose of the LAV-BPIFB4 longevity gene, these mice exhibited markedly enhanced cardiac performance, especially in diastolic function—the critical phase where the heart relaxes and replenishes with blood.
Beyond functional improvements, the gene therapy substantially diminished fibrosis, or scarring, in heart tissue and decreased the prevalence of senescent cells within the organ. Furthermore, it stimulated angiogenesis, the formation of new microvasculature, which could bolster overall cardiac vitality and durability.
Extending their work to human cells sourced from Progeria patients, the researchers confirmed that the longevity gene effectively curbed cellular senescence and fibrotic changes without directly modifying progerin concentrations. These findings indicate that LAV-BPIFB4 empowers cells to endure the poisonous repercussions of progerin, fortifying innate protective mechanisms rather than directly targeting the mutated protein.
A Fresh Strategy for Progeria Treatment and Cardiac Aging
Dr. Yan Qiu, an Honorary Research Fellow at the Bristol Heart Institute within the University of Bristol, commented: “Our investigation has pinpointed a safeguarding role for a supercentenarian-derived longevity gene in countering heart dysfunction associated with progeria, validated across both animal models and cellular systems.”
She continued: “These outcomes instill optimism for an innovative therapeutic paradigm for Progeria, one that leverages the inherent biology of successful aging over merely inhibiting the defective protein. Over time, this methodology may also prove effective against typical age-related cardiovascular ailments.”
“This study injects fresh optimism into the battle against Progeria and posits that the genetic makeup of supercentenarians might unlock novel interventions for premature or hastened cardiac senescence, potentially enabling longer, healthier lives for everyone.”
Future Prospects: Pioneering Anti-Aging Interventions
Professor Annibale Puca, who leads the research group at IRCCS MultiMedica and serves as Dean of the Faculty of Medicine at the University of Salerno, elaborated: “This represents the inaugural research demonstrating that a gene linked to longevity can neutralize the cardiovascular impairments wrought by progeria.”
He emphasized: “The discoveries lay the groundwork for groundbreaking treatment protocols tailored to this uncommon illness, which desperately needs advanced cardiovascular pharmaceuticals to enhance survival rates and elevate patients’ life quality. Moving forward, delivering the LAV-BPIFB4 gene via gene therapy might be substituted or augmented by innovative protein- or RNA-based delivery systems.”
Professor Puca concluded by noting ongoing initiatives: “We are actively pursuing multiple studies to explore LAV-BPIFB4’s capacity to mitigate declines in the cardiovascular and immune systems across diverse disease states, with the ultimate aim of converting these laboratory insights into a novel biologic therapeutic agent.”
